Company intelligence

RLMD

Relmada Therapeutics, Inc. · NASDAQ · Healthcare

Price$4.56-0.60% · −$0.03

Market cap478.55MEquity value

P / E-5.1Trailing ratio

Volume263.4KLatest session

Market data

RLMD price chart

TradingView

Related signals

1 min delayed

Browse public RLMD signals with their source context and measured market impact. Open any signal for its permanent analysis page.

RLMDJun 18, 2026+1.88% since signal

HC Wainwright Initiates RLMD Coverage With Buy on NMIBC NDV-01

HC Wainwright initiated coverage on RLMD with a Buy rating and a $12 target, highlighting NDV-01 for NMIBC. New Phase 2 interim data show high complete response rates, especially in BCG-unresponsive patients, and a provisional patent could extend protection to 2047. The stock has surged versus peers, reflecting a shift toward bladder-sparing regimens amid BCG shortages.

View signal analysis

RLMDDec 9, 2024+1.62% since signal

Relmada discontinues late-stage trials for depression drug, explores sale

Relmada suspended two late-stage studies for its depression drug. The company will seek strategic alternatives, including a possible sale.

View signal analysis

RLMDDec 4, 2024-29.91% since signal

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Reliance II Phase 3 study deemed futile for REL-1017 treatment efficacy. No new safety issues were reported despite disappointing trial results. Relmada plans to analyze full data for future REL-1017 program direction. The company's focus will remain on advancing the Phase 1 REL-P11 study. RLMD stock experienced a significant decline of 75.4% post-announcement.

View signal analysis

Research